Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure – Empire HF and SIMPLE
Empagliflozin treatment reduced body weight and hemoglobin A1c, and increased hematocrit. No changes were seen in concentrations of lipids and lipoproteins with empagliflozin compared to placebo. This suggests that the cardioprotective effects of SGLT2 inhibitors are independent of lipid and lipoprotein concentrations.
Authors
- Marianne Benn (ORCID: https://orcid.org/0000-0002-1701-595X)
- Frida Emanuelsson (ORCID: https://orcid.org/0000-0003-3024-2847)
- Morten Schou (ORCID: https://orcid.org/0000-0002-4271-2466)
- Louise Ellegaard Bechmann (ORCID: https://orcid.org/0000-0003-3855-6365)
- Mikkel Jürgens (ORCID: https://orcid.org/0000-0002-5942-9341)
- Massar Omar (ORCID: https://orcid.org/0000-0002-9634-3889)
- Caroline Kistorp (ORCID: https://orcid.org/0000-0002-3019-6775)
- Niels Brandt (ORCID: https://orcid.org/0000-0003-0067-1413)
- Emil List Larsen (ORCID: https://orcid.org/0000-0002-0676-0858)
- Børge Grønne Nordestgaard (ORCID: https://orcid.org/0000-0002-1954-7220)
- Jacob Eifer Møller (ORCID: https://orcid.org/0000-0003-2873-5845)
- J. Steen Jensen (ORCID: https://orcid.org/0000-0003-2821-9947)
Institutions
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1016/j.jacl.2024.12.015
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Hjerteforeningen
- Gentofte Hospital
- Region Hovedstaden
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- Hartmann Fonden
- Research and Innovation Foundation
- Fonden til Lægevidenskabens Fremme